Novartis Beovu Eye Disease Drug Nears Marketing Approval With CHMP Recommendation
December 13 2019 - 7:48AM
Dow Jones News
By Carlo Martuscelli
Novartis AG (NOVN.EB) said Friday that the European Union's
Committee for Medicinal Products for Human Use has given a positive
opinion on its Beovu medicine as a treatment for wet age-related
macular degeneration, bringing it to the verge of market
authorization in the bloc.
The committee recommended that the European Commission approve
the medicine to treat the eye disease following positive clinical
trial results, the Swiss drug maker said.
In most cases a recommendation by the CHMP leads to marketing
approval. Novartis said that it expects a decision to be made
within three months.
The U.S. Food and Drug Administration approved Beovu for wet AMD
in October.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com;
@carlomartu
(END) Dow Jones Newswires
December 13, 2019 07:33 ET (12:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024